Dr Sanjit Singh Lamba has been appointed as the Managing Director of Eisai Pharmaceuticals India
The two subsidiaries of Tokyo-headquartered Eisai Co, Eisai Pharmatechnology and Manufacturing located in Visakhapatnam and Eisai Pharmaceuticals India located in Mumbai have been amalgamated and the new entity shall be known as ‘Eisai Pharmaceuticals India.’ This information was given by Dr Sanjit Singh Lamba.
The amalgamation of the two subsidiaries was completed to leverage the capability of Eisai India’s state-of-the art integrated research and manufacturing operations with its specialised sales force to meet its business objectives in India. This also provides a more rationalised structure for better efficiency.
Lamba has been appointed as the Managing Director of Eisai Pharmaceuticals India, the merged entity.
In line with its human health care (hhc) mission, Eisai is committed to improving global access to medicines (ATM) over the medium- to long-term through partnership strategies that involve working with governments, international organisations, private entities and non-profit organisations.